These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2495750)

  • 1. Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects.
    Neri B; Bartalucci S; Pieri A; Gemelli MT; Rizzo M; Bartoletti R; Trippitelli A; Paoletti MC
    Anticancer Res; 1989; 9(1):13-6. PubMed ID: 2495750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does total androgen suppression in advanced prostatic cancer induce a greater number of complete remissions? A phase II trial].
    Germà Lluch JR; Izquierdo Delso MA; Seguí Palmer MA; Villavicencio H; Ojeda González B; de Andrés Basauri L; Pallarés Curto C
    Actas Urol Esp; 1991; 15(1):34-8. PubMed ID: 1905458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD; Horlbeck R; Klippel KF
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
    Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
    Akaza H
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
    Aso Y; Akaza H; Koiso K; Kameyama S; Koyanagi T; Kawai T; Kumamoto Y; Tazaki H; Funyu T; Oshima H
    Hinyokika Kiyo; 1993 Apr; 39(4):391-403. PubMed ID: 8503339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
    Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
    BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life among patients with metastatic prostate cancer.
    Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
    Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.